Roivant Sciences Ltd. (ROIV) stock
ROIVNasdaqPharmaceutical PreparationsFiscal year ends March 31
$39.53−0.46 (-1.15%)
Close on Nov 13, 2026Market cap $28.55BP/E –Yield –
Roivant Sciences ebitda
EBITDA is earnings before interest, taxes, depreciation and amortization, a rough measure of cash profit from operations.
Roivant Sciences's ebitda for the twelve months ending Sep 30, 2026 was -$555.42M. For fiscal 2025 it was -$511.72M. The highest annual figure on record is $4.52B in fiscal 2023.
Annual ebitda
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Mar 31, 2026 | -$511.72M | – |
| FY2024 | Mar 31, 2025 | -$989.22M | -121.9% |
| FY2023 | Mar 31, 2024 | $4.52B | – |
| FY2022 | Mar 31, 2023 | -$887.91M | – |
| FY2021 | Mar 31, 2022 | -$1.35B | – |
Quarterly ebitda
Change is against the same quarter a year earlier.
Periods
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026CQ3 2026 | Sep 30, 2026 | -$267.45M | – |
| Q1 FY2026CQ2 2026 | Jun 30, 2026 | -$365.39M | – |
| Q4 FY2025CQ1 2026 | Mar 31, 2026 | $415.88M | – |
| Q3 FY2025CQ4 2025 | Dec 31, 2025 | -$338.46M | – |
| Q2 FY2025CQ3 2025 | Sep 30, 2025 | -$305.31M | – |
| Q1 FY2025CQ2 2025 | Jun 30, 2025 | -$283.82M | – |
| Q4 FY2024CQ1 2025 | Mar 31, 2025 | -$283.54M | – |
| Q3 FY2024CQ4 2024 | Dec 31, 2024 | -$271.46M | -105.3% |
| Q2 FY2024CQ3 2024 | Sep 30, 2024 | -$336.87M | – |
| Q1 FY2024CQ2 2024 | Jun 30, 2024 | -$97.35M | – |
| Q4 FY2023CQ1 2024 | Mar 31, 2024 | -$201.61M | -599.7% |
| Q3 FY2023CQ4 2023 | Dec 31, 2023 | $5.13B | – |
| Q2 FY2023CQ3 2023 | Sep 30, 2023 | -$208.30M | – |
| Q1 FY2023CQ2 2023 | Jun 30, 2023 | -$270.57M | – |
| Q4 FY2022CQ1 2023 | Mar 31, 2023 | $40.34M | – |
| Q3 FY2022CQ4 2022 | Dec 31, 2022 | -$372.93M | – |
| Q2 FY2022CQ3 2022 | Sep 30, 2022 | -$275.69M | – |
| Q1 FY2022CQ2 2022 | Jun 30, 2022 | -$279.63M | – |
| Q4 FY2021CQ1 2022 | Mar 31, 2022 | -$265.10M | – |
| Q3 FY2021CQ4 2021 | Dec 31, 2021 | -$244.65M | – |
See a number that looks wrong?